Corporate Profile

Eargo is a medical device company on a mission to improve hearing health. Our innovative product and go-to-market approach address the major challenges of traditional hearing aid adoption, including social stigma, accessibility and cost. We believe our Eargo hearing aids are the first virtually invisible, rechargeable, completely-in-canal, FDA-regulated, exempt Class I or Class II devices indicated to compensate for mild to moderate hearing loss. Our differentiated, consumer-first approach empowers consumers to take control of their hearing. Consumers can purchase online or over the phone and get personalized and convenient consultation and support from hearing professionals via phone, text, email or video chat. The Eargo device is offered to consumers at approximately half the cost of competing hearing aids purchased through traditional channels in the United States.

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

08 Nov '22
DEADLINE TO PARTICIPATE IN EARGO RIGHTS OFFERING FOR U.S. REGISTERED HOLDERS: 5:00 P.M., NEW YORK CITY TIME, ON NOVEMBER 17, 2022 DEADLINE TO PARTICIPATE IN EARGO RIGHTS OFFERING FOR U.S. HOLDERS WHO HOLD SHARES THROUGH A BROKERAGE ACCOUNT: 2:15 P.M., NEW YORK CITY TIME, ON NOVEMBER 17, 2022
07 Nov '22
SAN JOSE, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. (“Eargo” or the “Company”) (NASDAQ: EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced the filing of Eargo’s Quarterly Report on Form 10-Q for the quarterly period